NDA 206829 · Cubist Pharms LLC
Zerbaxa
Ceftolozane Sulfate, Tazobactam Sodium · Intravenous
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: May 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Dec 19, 2014
Approved uses
5
Original approval plus efficacy supplements
Registered trials
26
7 Phase 3, 2 recruiting
FAERS reports
982
670 serious, 233 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 12, 2026.
ZERBAXA (ceftolozane and tazobactam) is a combination of ceftolozane, a cephalosporin antibacterial, and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible microorganisms in adult and pediatric patients (at least 32 weeks gestational age): Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole. ( 1.1 ) Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis. ( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP). ( 1.3 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZERBAXA and other antibacterial drugs, ZERBAXA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.4 ) 1.1 Complicated Intra-abdominal Infections ZERBAXA used in combination with metronidazole is indicated for the treatment of adult and pediatric patients (at least 32 weeks gestational age) with complicated intra-abdominal infections (cIAI) caused by the following susceptible Gram-negative and Gram-positive microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, and Streptococcus salivarius . 1.2 Complicated Urinary Tract Infections, Including Pyelonephritis ZERBAXA is indicated for the treatment of adult and pediatric patients (at least 32 weeks gestational age) with complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible Gram-negative microorganisms: Escherichia coli ,...
Mechanism: ZERBAXA is an antibacterial drug [see Clinical Pharmacology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 12, 2026 Supplement 23 · Efficacy · priority review LetterLabel
- Apr 21, 2022 Supplement 11 · Efficacy LetterLabel
- Apr 21, 2022 Supplement 12 · Efficacy LetterLabel
- Jun 3, 2019 Supplement 8 · Efficacy · priority review LetterLabelReview
- Dec 19, 2014 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelLabelSummary ReviewLetter
1 products under this application
- ZERBAXA · CEFTOLOZANE SULFATE EQ 1GM BASE/VIAL; TAZOBACTAM SODIUM EQ 0.5GM BASE/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ceftolozane" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)Pivotal-lookingCompleted
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT02070757 · 726 participants · Start Sep 2, 2014 · Primary completion May 15, 2018
Drug: Ceftolozane/tazobactam; Meropenem · For: Healthcare-Associated Pneumonia; Ventilator-Associated Pneumonia; Lung Diseases
- Optimising TREATment for Severe Gram-Negative Bacterial InfectionsPivotal-lookingRecruiting
National University of SingaporeAcademic, hospital or other
NCT07004049 · 600 participants (planned) · Start Apr 21, 2025 · Primary completion Dec 31, 2028
Drug: Colistin/Polymyxin B + Sulbactam; Colistin/Polymyxin B + Tigecycline/Eravacycline and 12 more · For: Bloodstream Infection; Ventilator Associated Bacterial Pneumonia; Hospital Acquired Bacterial Pneumonia and 2 more
Sites: Brisbane, Australia; Hangzhou, China; Xi'an, China · 41 sites in all
- Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03830333 · 268 participants · Start Mar 20, 2019 · Primary completion Oct 14, 2020
Drug: Ceftolozane/Tazobactam; Metronidazole and 2 more · For: Complicated Intra-abdominal Infections
Sites: Hefei, China; Beijing, China; Guangzhou, China · 25 sites in all
- Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological PatientsPivotal-lookingStatus unknown
Instituto Nacional de Cancerologia de MexicoAcademic, hospital or other
NCT06422533 · 226 participants (planned) · Start Nov 7, 2023 · Primary completion Jul 31, 2025
Drug: Ceftolozane/tazobactam; Piperacillin/tazobactam · For: Hematologic Neoplasms; Neutropenia
Sites: Mexico City, Mexico
- MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03230838 · 134 participants · Start Apr 26, 2018 · Primary completion Dec 3, 2020
Drug: Ceftolozane/Tazobactam; Meropenem · For: Complicated Urinary Tract Infection; Pyelonephritis
Sites: Los Angeles, California; Orange, California; San Diego, California · 52 sites in all
- Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract InfectionsPivotal-lookingCompleted
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT00921024 · 129 participants · Start Jun 30, 2009 · Primary completion Feb 25, 2010
Drug: CXA-101; Ceftazidime · For: Complicated Urinary Tract Infection
Sites: Los Angeles, California; Orlando, Florida; Decatur, Georgia · 21 sites in all
- Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal InfectionsPivotal-lookingCompleted
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT01147640 · 122 participants · Start Jun 25, 2010 · Primary completion Feb 20, 2011
Drug: CXA-101/ tazobactam and metronidazole; meropenem plus saline placebo · For: Complicated Intra-abdominal Infection
Sites: Orange, California; Torrance, California; Aurora, Colorado · 33 sites in all
- Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02728089 · 115 participants · Start Apr 14, 2016 · Primary completion Sep 5, 2017
Drug: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) · For: Urinary Tract Infection (UTI); Complicated Urinary Tract Infection; Pyelonephritis and 1 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use139
- product use in unapproved indication128
- no adverse event90
- death81
- product use issue67
- pathogen resistance54
- drug ineffective44
- acute kidney injury36
- drug resistance30
- encephalopathy27
- incorrect dose administered26
- pancytopenia26
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 45 |
| 2016 | 85 |
| 2017 | 126 |
| 2018 | 135 |
| 2019 | 126 |
| 2020 | 145 |
| 2021 | 42 |
| 2022 | 55 |
| 2023 | 82 |
| 2024 | 67 |
| 2025 | 49 |
| 2026 | 25 |
Recalls
1 FDA enforcement reports for this application.
Dec 21, 2020 · Class II · Terminated
Lack of assurance of sterility: The results of sterility tests of seven batches of product were out of specification. Five of these batches tested positive for Ralstonia pickettii and two batches produced turbid results...
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zerbaxa (Ceftolozane/Tazobactam)
2024 spending
$18.0M
Beneficiaries
1,128
5,087 claims
Per beneficiary
$15,974
$24.65 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $8,252,292 |
| 2021 | $52,147 |
| 2022 | $7,206,260 |
| 2023 | $12,776,957 |
| 2024 | $18,018,166 |
Part B: Zerbaxa (Ceftolozane/Tazobactam) · HCPCS J0695
2024 spending
$280K
Beneficiaries
126
499 claims
Per beneficiary
$2,222
2024 ASP limit $7.78 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $693,355 |
| 2021 | $8,380 |
| 2022 | $401,270 |
| 2023 | $213,774 |
| 2024 | $279,922 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Scudeller L, Righi E, Chiamenti M, et al. · Int J Antimicrob Agents 2021 · Systematic Review, Network Meta-Analysis
- Efficacy of treatment options for complicated urinary tract infections including acute pyelonephritis: a systematic literature review and network meta-analysis.
Wagenlehner F, Caballero VR, Maheshwari V, et al. · J Comp Eff Res 2025 · Systematic Review, Network Meta-Analysis
- A Systematic Review of the Pharmacokinetics and Pharmacodynamics of Novel Beta-Lactams and Beta-Lactam with Beta-Lactamase Inhibitor Combinations for the Treatment of Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria.
Rando E, Novy E, Sangiorgi F, et al. · Int J Antimicrob Agents 2024 · Systematic Review
- Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
Kong W, Deng T, Li S, et al. · BMC Infect Dis 2023 · Systematic Review, Network Meta-Analysis
- Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
Kollef MH, Nováček M, Kivistik Ü, et al. · Lancet Infect Dis 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
- Comparison of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant/Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections: A Systematic Review and Meta-analysis.
Gatti M, De Paola R, Giorgi B, et al. · Clin Infect Dis 2026 · Systematic Review, Meta-Analysis
Sponsor: Cubist Pharms LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.